Want to see ARAI full AI Analyst Report?
Top Page
Arrive AI Inc.
(NASDAQ:ARAI)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.11
▼(-55.42% Downside)
Action:Reiterated
Date:10/14/26
The score is driven primarily by weak financial performance (minimal and declining revenue, large losses, and ongoing free-cash-flow burn) and bearish technical trends (below major moving averages with negative MACD). Offsetting these are modest positives from improved balance-sheet leverage and a cautiously optimistic earnings narrative (product milestones, IP strength, and financing optionality), though near-term runway and dilution/listing risks remain material.
Positive Factors
Intellectual Property
A growing patent portfolio can support differentiation in autonomous logistics and create barriers to competing infrastructure providers. Issued and pending protection across U.S. and international markets gives the company a durable foundation as it pursues commercialization and expands its product roadmap.
Negative Factors
Minimal Revenue and Deep Losses
The company has not yet achieved meaningful commercial scale, while revenue is shrinking and gross profit has turned negative. Losses that are extremely large relative to sales indicate limited operating leverage and make sustained external funding or major execution gains important to future viability.
Read all positive and negative factors
Positive Factors
Negative Factors
Intellectual Property
A growing patent portfolio can support differentiation in autonomous logistics and create barriers to competing infrastructure providers. Issued and pending protection across U.S. and international markets gives the company a durable foundation as it pursues commercialization and expands its product roadmap.
Read all positive factors
Arrive AI Inc. (ARAI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.75M
Dividend YieldN/A
Average Volume (3M)9.28M
Price to Earnings (P/E)―
Beta (1Y)4.09
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees50
SectorGeneral
Sector StrengthN/A
IndustrySoftware - Application
Share Statistics
EPS (TTM)-0.75
Shares Outstanding52,260,822
10 Day Avg. Volume3,184,244
30 Day Avg. Volume9,281,471
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)34.20
Price to Sales (P/S)747.67
P/FCF Ratio-9.68
Enterprise Value/Market Cap3.79
Enterprise Value/Revenue417.52
Enterprise Value/Gross Profit-5.36K
Enterprise Value/Ebitda-0.86
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.58
Revenue Forecast (FY)$100.00K
Arrive AI Inc. Business Overview & Revenue Model
Company Description
Arrive AI Inc. operates a subscription-based "Mailbox-as-a-Service" platform. This innovative system facilitates the automated, on-demand, and secure delivery of various goods, including packages, products, and food. It boasts intelligent, climate...
How the Company Makes Money
null...
Arrive AI Inc. Earnings Call Summary
Earnings Call Date:Aug 13, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Apr 21, 2027
Earnings Call Sentiment Neutral
The call presented a balanced picture: meaningful commercial momentum (partnerships, pilot deployments, AP3 Plus readiness), a strengthening IP position, and renewed financing optionality are offset by stagnant quarter-over-quarter revenue, an increased reported net loss (largely driven by a one-time non-cash conversion expense), limited cash runway at current burn rates, and a small installed base that must scale. Management emphasized progress and optionality rather than imminent revenue scale, suggesting cautious optimism but material execution and financing risks remain.Positive Updates
Commercial Partnerships and Pilot Momentum
Multiple strategic partnerships and pilot engagements across healthcare, manufacturing and specialty pharmacy delivery, including Nexus AMR integration, an expanded deployment with Hancock Regional Hospital (added an Arrive Point for building-to-building movement), a partnership with DXC for pharmaceutical manufacturing facilities, a letter of intent with LifeSpan Pharmacy and CarDon for drone pharmacy delivery, and early-stage discussions with several Fortune 500 companies.
Negative Updates
Flat Revenue Quarter-over-Quarter
Second quarter revenue was in line with Q1 at $14,700, representing 0% change quarter-over-quarter. Management noted that, excluding a non-recurring consulting project in the year-ago quarter, revenue was 'up slightly' year-over-year, but no percentage was provided.
Read all updates
Q2-2026 Updates
Positive
Negative
Commercial Partnerships and Pilot Momentum
Multiple strategic partnerships and pilot engagements across healthcare, manufacturing and specialty pharmacy delivery, including Nexus AMR integration, an expanded deployment with Hancock Regional Hospital (added an Arrive Point for building-to-building movement), a partnership with DXC for pharmaceutical manufacturing facilities, a letter of intent with LifeSpan Pharmacy and CarDon for drone pharmacy delivery, and early-stage discussions with several Fortune 500 companies.
Read all positive updates
Company Guidance
Management gave concrete near‑term and medium‑term milestones and financial metrics: they expect more than a dozen AP3 Plus Arrive Points in stock and ready to ship by mid‑September, AP4 targeted for Q1 2027 with the supply chain designed to scale to hundreds in 2027 (and thousands/tens of thousands for later generations), and the Hancock expansion should drive incremental revenue in Q3 and Q4; Avride expects to be operating on more than 20 campuses by year‑end. Financials/guidance: Q2 revenue was $14,700 (flat with Q1), reported Q2 net loss was $14.1M versus $3.7M in Q2 2025 (including $9.7M of non‑cash note conversion expense), non‑GAAP Q2 net loss was $4.3M, cash and liquid investments were $5.1M at June 30 (up from $2.1M at Dec. 31), and cash burn is ~ $1.1M/month; financing optionality includes an S‑3 registration for up to $100M, an ATM with ~ $15M capacity, and ~$19M available prepaid‑advance capacity under the 2025 equity line. Pipeline/IP: multiple commercialization conversations with a meaningful subset in second‑/third‑round talks, 10 U.S. issued patents and 4 pending, ~13 issued international patents (including a recent EU approval) and ~19 ideas in the development pipeline.Arrive AI Inc. Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
44
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 52.15K | 113.25K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -4.06K | 113.25K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -25.25M | -12.23M | -4.50M | -7.30M | -2.37M | -1.54M |
| Net Income | -26.60M | -12.83M | -4.54M | -7.32M | -2.39M | -1.53M |
Balance Sheet | ||||||
| Total Assets | 12.47M | 10.93M | 987.79K | 619.60K | 2.53M | 3.21M |
| Cash, Cash Equivalents and Short-Term Investments | 5.14M | 2.10M | 129.32K | 325.47K | 1.56M | 2.68M |
| Total Debt | 5.44M | 6.26M | 19.08K | 27.04K | 33.69K | 0.00 |
| Total Liabilities | 7.70M | 8.46M | 1.97M | 1.10M | 165.75K | 49.39K |
| Stockholders Equity | 4.77M | 2.48M | -983.17K | -477.77K | 2.37M | 3.16M |
Cash Flow | ||||||
| Free Cash Flow | -11.60M | -8.75M | -2.40M | -2.92M | -2.26M | -1.85M |
| Operating Cash Flow | -10.71M | -8.25M | -2.29M | -2.82M | -1.84M | -1.48M |
| Investing Cash Flow | -2.79M | -362.08K | -114.66K | -104.99K | -426.14K | -370.50K |
| Financing Cash Flow | 15.87M | 10.59M | 2.21M | 1.69M | 1.14M | 4.25M |
Arrive AI Inc. Technical Analysis
Negative
0.24
Price Trends
0.20
Negative
0.28
Negative
0.71
Negative
Market Momentum
-0.03
Positive
25.80
Positive
12.78
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARAI, the sentiment is Negative. The current price of 0.24 is above the 20-day moving average (MA) of 0.16, above the 50-day MA of 0.20, and below the 200-day MA of 0.71, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 25.80 is Positive, neither overbought nor oversold. The STOCH value of 12.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARAI.
Arrive AI Inc. Risk Analysis
Arrive AI Inc. disclosed 49 risk factors in its most recent earnings report. Arrive AI Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Arrive AI Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $752.48M | -2,426.19 | -0.03% | ― | ― | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
47 Neutral | $72.75M | -0.47 | -249.64% | ― | -1.81% | 46.29% | |
47 Neutral | $58.73M | -1.30 | -88.73% | ― | 250.00% | 35.86% | |
46 Neutral | $1.36B | -6.16 | -21.63% | ― | 108.63% | 40.63% | |
44 Neutral | $5.75M | -0.15 | -730.42% | ― | ― | ― | |
44 Neutral | $38.74M | -1.69 | -59.05% | ― | 9.78% | 69.23% |
* General Sector Average
ARAI
Arrive AI Inc.
0.11
-4.93
-97.82%
VERI
Veritone
0.60
-5.77
-90.61%
REKR
Rekor Systems
0.28
-2.28
-89.02%
ARBE
Arbe Robotics
0.46
-1.47
-76.27%
CGNT
Cognyte Software
10.19
1.74
20.59%
WRD
WeRide
4.37
-6.73
-60.63%
Arrive AI Inc. Corporate Events
Business Operations and StrategyExecutive/Board ChangesProduct-Related Announcements
Arrive AI Launches New Defense Logistics Division
Positive
Oct 13, 2026
On October 12, 2026, Arrive AI announced the launch of Arrive AI Defense, a new division dedicated to adapting its autonomous delivery infrastructure and intelligent logistics technologies for defense, military, diplomatic and national security us...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Arrive AI announces premium-priced PIPE financing transaction
Positive
Oct 9, 2026
On October 5, 2026, Arrive AI Inc. completed a $250,000 private investment in public equity transaction with a U.S.-based specialized private investment firm, issuing 384,615 common shares and an equal number of warrants at $0.65 per unit. The pri...
Executive/Board Changes
Arrive AI Announces Resignation of Chief Operating Officer
Neutral
Sep 29, 2026
Arrive AI Inc. operates in the technology sector, but the company’s specific products, services, and market focus were not detailed in the disclosure.On September 24, 2026, Arrive AI Inc. announced that Chief Operating Officer Mark Hamm had ...
Business Operations and StrategyRegulatory Filings and Compliance
Arrive AI Posts New Investor Presentation Under Reg FD
Neutral
Sep 8, 2026
On September 8, 2026, Arrive AI, Inc. posted an investor presentation to its website and furnished it as an exhibit to a Form 8-K, providing additional information to current and prospective shareholders. The company emphasized that the materials ...
Business Operations and StrategyPrivate Placements and Financing
Arrive AI Secures Financing and Cuts Workforce to Reduce Costs
Negative
Aug 19, 2026
On August 6, 2026, Arrive AI Inc.’s volume-weighted average price fell below a $0.25 floor under an existing securities purchase agreement, triggering mandatory monthly cash repayments tied to earlier pre-paid share purchases. To manage thes...
Executive/Board Changes
Arrive AI Appoints Veteran Executive as New CFO
Positive
Aug 12, 2026
On August 10, 2026, Arrive AI Inc.’s board appointed veteran capital markets executive Piyush Phadke as chief financial officer, with his duties to begin on August 17, 2026. Under an at‑will employment agreement, he will report to the ...
Executive/Board Changes
Arrive AI Announces Recent CFO and Board Resignations
Negative
Jul 31, 2026
Arrive AI Inc. reported leadership changes in late July 2026, marking a shift in its senior management and board composition. On July 27, 2026, Chief Financial Officer Todd Pepmeier submitted his resignation, effective August 10, 2026, and on July...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.